Haemonetics Stock Alpha and Beta Analysis

HAE Stock  USD 50.60  0.55  1.08%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Haemonetics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Haemonetics over a specified time horizon. Remember, high Haemonetics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Haemonetics' market risk premium analysis include:
Beta
1.92
Alpha
(0.66)
Risk
3.73
Sharpe Ratio
(0.13)
Expected Return
(0.48)
Please note that although Haemonetics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Haemonetics did 0.66  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Haemonetics stock's relative risk over its benchmark. Haemonetics has a beta of 1.92  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Haemonetics will likely underperform. At present, Haemonetics' Enterprise Value Over EBITDA is projected to drop based on the last few years of reporting. The current year's Price Book Value Ratio is expected to grow to 5.13, whereas Book Value Per Share is forecasted to decline to 14.26.

Haemonetics Quarterly Cash And Equivalents

306.76 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Haemonetics Backtesting, Haemonetics Valuation, Haemonetics Correlation, Haemonetics Hype Analysis, Haemonetics Volatility, Haemonetics History and analyze Haemonetics Performance.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Haemonetics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Haemonetics market risk premium is the additional return an investor will receive from holding Haemonetics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Haemonetics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Haemonetics' performance over market.
α-0.66   β1.92

Haemonetics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Haemonetics' Buy-and-hold return. Our buy-and-hold chart shows how Haemonetics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Haemonetics Market Price Analysis

Market price analysis indicators help investors to evaluate how Haemonetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Haemonetics shares will generate the highest return on investment. By understating and applying Haemonetics stock market price indicators, traders can identify Haemonetics position entry and exit signals to maximize returns.

Haemonetics Return and Market Media

The median price of Haemonetics for the period between Sun, Jun 22, 2025 and Sat, Sep 20, 2025 is 71.08 with a coefficient of variation of 16.63. The daily time series for the period is distributed with a sample standard deviation of 10.76, arithmetic mean of 64.67, and mean deviation of 10.51. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Integer appoints former iRhythm CEO to board
07/11/2025
2
Acquisition by Robert Abernathy of 2693 shares of Haemonetics subject to Rule 16b-3
07/24/2025
3
Peering Into Haemoneticss Recent Short Interest
08/06/2025
4
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
08/08/2025
5
Earnings Result Leaves CSL Bloodied
08/21/2025
6
Spotting Winners Enovis And Medical Devices Supplies - Specialty Stocks In Q2
08/27/2025
7
Royce Small-Cap Trust as of Jul 31, 2025
09/02/2025
8
How sensitive is Haemonetics Corporation to inflation - 2025 Trading Recap Free Low Drawdown Momentum Trade Ideas - Lancaster City Council
09/09/2025
9
Haemonetics stock hits 52-week low at 50.62 USD - Investing.com
09/16/2025
10
1 Profitable Stock for Long-Term Investors and 2 That Underwhelm
09/19/2025

About Haemonetics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Haemonetics or other stocks. Alpha measures the amount that position in Haemonetics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2011 2017 2023 2025 (projected)
Days Sales Outstanding62.8955.9554.3661.06
PTB Ratio2.835.143.875.13

Haemonetics Upcoming Company Events

As portrayed in its financial statements, the presentation of Haemonetics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Haemonetics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Haemonetics. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.
8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

Build Portfolio with Haemonetics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Haemonetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Haemonetics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Haemonetics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...